http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102297505-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2016-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102297505-B1 |
| titleOfInvention | Methods for screening anti-cancer drugs inhibiting interactions between AIMP2-DX2 and HSP70 |
| abstract | The present invention relates to a method for screening an anticancer agent that inhibits the binding of AIMP2-DX2 to HSP70, and more particularly, to a method comprising: contacting AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof in the presence or absence of a test substance; measuring the binding of AIMP2-DX2 to HSP70; determining a change in the binding level of AIMP2-DX2 and HSP70 by the test substance; selecting a test substance that reduces the binding level of AIMP2-DX2 and HSP70; And it relates to an anticancer agent screening method comprising the step of confirming the anticancer activity of the selected test substance in cells or animals, and to an anticancer composition comprising the anticancer agent selected by the method as an active ingredient. Based on the discovery that HSP70 is a regulator that directly binds to and stabilizes AIMP2-DX2, which is important for cancer development and progression, it can be usefully used to develop anticancer agents with a completely new mechanism of action. In addition, the pharmaceutical composition for preventing or treating cancer comprising the anticancer agent selected according to the method of the present invention as an active ingredient suppresses the expression of HSP70 or inhibits the binding of HSP70 and AIMP2-DX2 to lower the level of AIMP2-DX2 protein, Since it can effectively prevent cancer progression, it can be usefully used to develop cancer therapeutic agents. |
| priorityDate | 2016-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 625.